Sprint Bioscience

Sprint Bioscience Current Assets

The Current Assets of Sprint Bioscience (SPRINT.ST) as of Oct 11, 2026 is 126.70 M SEK. In the previous year, Current Assets was 37.24 M SEK — a change of 240.21% (higher).

Current Assets

126.70 MSEK

YoY

240.21%

Last updated:

Current Assets of Sprint Bioscience is 2025 126.70 M SEK. Current Assets of Sprint Bioscience was 2024 37.24 M SEK. It decreases by 240.21% higher compared to the previous year.

The Sprint Bioscience Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
19.54 M SEK
Jan 1, 2019
19.22 M SEK
Jan 1, 2020
37.25 M SEK
Jan 1, 2021
75.92 M SEK
Jan 1, 2022
34.87 M SEK
Jan 1, 2023
49.93 M SEK
Jan 1, 2024
37.24 M SEK
Jan 1, 2025
126.70 M SEK
The Sprint Bioscience Current Assets history
YEARCurrent AssetsYoY
126.70 MSEK+240.21%
37.24 MSEK-25.42%
49.93 MSEK+43.18%
34.87 MSEK-54.06%
75.92 MSEK+103.84%
37.25 MSEK+93.80%
19.22 MSEK-1.64%
19.54 MSEK+205.90%
6.39 MSEK-73.75%
24.33 MSEK+645.04%
3.27 MSEK-79.64%
16.04 MSEK+1,667.03%
907,698.00SEK-73.35%
3.41 MSEK+563.67%
513,262.00SEK—
Access this data via the Eulerpool API

Sprint Bioscience Stock analysis

What does Sprint Bioscience do? The Swedish company Sprint Bioscience AB is an innovative developer of drugs targeted for use in cancer. The company was founded in Stockholm in 2009 and has since worked with a strong focus on molecular research. Sprint Bioscience is a biotechnology company with the goal of developing drugs for various types of cancer. The company's focus is on so-called "trickster molecules" that can prevent tumor cells from taking up nutrients, ultimately leading to their death. The innovative business model of Sprint Bioscience is that they focus on the discovery and development of molecules, which they then sell to larger pharmaceutical companies that further develop and bring them to market. Sprint Bioscience has a wide range of molecular tools that allow for the identification, development, and optimization of cancer therapy drugs. The company aims to accelerate the discovery of new drugs in the field of oncology. Sprint Bioscience is divided into two business areas: discovery, which specializes in the identification and optimization of drugs for use in cancer, and development, which focuses on the preclinical development of drugs that are later further developed by larger pharmaceutical companies. The most well-known product of Sprint Bioscience is the molecule "SB-11285", a novel cancer therapeutic specifically developed for ovarian cancer. The molecule is intended to help destroy cancer cells by disrupting their cellular metabolism and depriving them of their energy source. Sprint Bioscience has also formed partnerships with other companies to exchange technologies and expertise. For example, there is a collaboration with Bayer to develop new oncology drugs. Overall, Sprint Bioscience has undergone significant development in recent years. The company has built strong expertise in the field of molecular research and effectively implemented its business model. Sprint Bioscience presents itself as a promising player in the biotechnology industry and has the potential to achieve further significant progress in the coming years. Sprint Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sprint Bioscience stock

Current Assets of Sprint Bioscience is 126.70 M SEK in 2025.

Current Assets of Sprint Bioscience changed from 37.24 M SEK to 126.70 M SEK, representing a 240.21% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Sprint Bioscience since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Sprint Bioscience historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Sprint Bioscience

All Key Metrics — Sprint Bioscience